


Arome Science, Inc. (Arome)
400 Farmington Avenue
Farmington, CT, 06032



Alexey V. Melnik
T 858-380-8686
www.arome-science.com
alexey@arome-science.com

Industry:

Biotech, Diagnostics

Management:

Alexey V. Melnik, CEO
Alexander A. Aksenov, CSO

Board:

Alexey V. Melnik, CEO
Alexander A. Aksenov, CSO
Silverio Iacono, CCO
Evguenia Kopylova

Scientific Advisory Board:

Pieter C. Dorrestein, Ph.D.
Geoff Feld, Ph.D.
Stephen Barns, Ph.D.
Denise Winokur, MBA, Ph.D.
Kirill Veselkov, Ph.D.
Jasdeep Singh, MBA

Number of Employees:

Finance:

Auditor's Name
Accounting Resourse Inc.

Funding to Date:
Founders: \$80,000
Financing Sought: \$2.75M
For:
Pilot Studies
R&D
IP
Operating Costs
Overhead

IP(seeking):

Licensing
Patents for workflows/software

Legal:

Wiggin and Dana LLP

Business Description / Company Background:

Arome Science Inc. is a company focused on understanding the role of gut microbes in human health and disease. Arome has been providing chemical analysis using semi-targeted metabolomics since 2018 to life science companies ranging from start-ups to large pharma. Arome provided actionable insights to companies in their R&D and pre-clinical studies publishing scientific findings along the way. Since the inception company has generated over \$1M in revenue and provided services to more than 30 organizations.

Market Opportunity / Unmet Need:

The global metabolomics market is a \$2.1B market with a CAGR of 13% through 2030 while the direct-to-consumer clinical testing market is \$3B and has a CAGR of 34%. Arome anticipates targeting Inflammatory Bowel Disease and Nonalcoholic Fatty Liver Disease for a beachhead market. Both illnesses are on the rise and benefit from early detection to reduce treatment which collectively cost the US \$50B a year.

Products / Services – Launched & Pipeline:

Arome Science is developing a consumer test to identify early signs of microbial imbalance and associated pathology. The test will include the analysis of urine, stool, and blood The company is initially focusing on NAFLD and IBD and is partnering with a private hospital that specializes in gut issues to validate its test.

Commercial / Technical Milestones:

Urine test for NAFLD, IBD – by the end of 2023. Blood test co-developed with manufacturing partner Q1 of 2024. Stool test co-developed with manufacturing partner Q2 of 2024. Combined test launch by the end of 2024.

Competition / Competitive Advantages / Customer Benefits:

Metabolon, Inc., Sapient Bio, Zoe, Ltd., Axis Pharm

Financial Projections (Unaudited):

Arome will provide test via point-of-care phisicians initially followed by the public launch with ability to procure test via internet

	2023	2024	2025	2026
Revenue (in thousands)	\$2,700	\$18,000	\$90,000	\$270,000
Growth Rate		567%	400%	200%
Growth Profit	\$900	\$3,600	\$15,000	\$30,000
Growth Margin	33%	20%	17%	11%